Q3 2026 (Media)
Logotype for Merck KGaA

Merck (MRK) Q3 2026 (Media) earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Merck KGaA

Q3 2026 (Media) earnings summary

12 Nov, 2026

Executive summary

  • Q3 net sales rose 5.1% organically to €5.627bn; growth was led by Life Science and Electronics, including Process Solutions, Rare Diseases and Semiconductor Solutions.

  • FY26 guidance was raised, reflecting stronger underlying performance and more favorable FX effects.

Financial highlights

  • Reported net sales increased 5.8% YoY to €5.627bn; organic growth was 5.1%, with a 1.5% FX benefit and a 0.8% portfolio drag.

  • EBITDA pre was €1.682bn, up 0.8% reported and 0.4% organically; prior-year EBITDA pre included one-time benefits.

  • Reported EBIT fell 46.5% to €653m and profit after tax fell 49.9% to €450m; EPS was €1.04 versus €2.07 YoY.

  • EPS pre was unchanged at €2.32; operating cash flow rose 9.4% to €1.660bn.

  • Net financial debt was €7.733bn at September 30, down 10.3% since year-end 2025; net financial debt to EBITDA pre was 1.2x.

Outlook and guidance

  • FY26 net sales guidance: €21.5–21.9bn, with organic growth of 3%–4% and FX impact of -1% to 0%.

  • FY26 EBITDA pre guidance: €6.2–6.4bn, with organic growth of 3%–5% and FX impact of -2% to 0%; EPS pre is €8.30–8.70.

  • FY26 free cash flow is expected at €2.3–2.7bn; guidance assumes a 22% underlying tax rate, Bio-Techne contribution for December, and no U.S. Mavenclad sales from November.

  • Life Science FY26 guidance: sales €9.4–9.6bn and EBITDA pre €2.75–2.85bn; organic growth of 6%–7% and 6%–8%, respectively.

  • Healthcare guidance: sales €8.5–8.7bn and EBITDA pre €2.9–3.0bn; Electronics guidance: sales ~€3.6bn and EBITDA pre ~€1.1bn.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Merck